Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Michelson

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
Biological Psychiatry|January 7, 2003
Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatmentMichael E Henry, Marc J Kaufman, John Hennen, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 23, 2005
Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptomsChristopher J Kratochvil, Jeffrey H Newcorn, L Eugene Arnold, et al.
Clinical and Translational Science|November 24, 2019
Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine TreatmentChi-Chung Li, Tiffini Voss, Ken Kowalski, et al.
The Journal of Pediatrics|April 7, 2005
Patterns of brain injury in term neonatal encephalopathySteven P Miller, Vijay Ramaswamy, David Michelson, et al.
Alzheimer'S Research & Therapy|August 8, 2019
Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's diseaseMichael F Egan, Yuki Mukai, Tiffini Voss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2009
Under the radar: balamuthia amebic encephalitisFrederick L Schuster, Shigeo Yagi, Shilpa Gavali, et al.
Cephalalgia : an International Journal of Headache|June 20, 2012
Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment designTony W Ho, Eric Pearlman, Donald Lewis, et al.
The Lancet. Neurology|April 1, 2014
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trialDavid Michelson, Ellen Snyder, Erin Paradis, et al.
Psychopharmacology|March 8, 2017
Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 dataW Joseph Herring, Kathryn M Connor, Ellen Snyder, et al.
Cephalalgia : an International Journal of Headache|May 1, 2015
Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraineTony W Ho, Andrew P Ho, Yang Joy Ge, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Biological Psychiatry|January 7, 2003
Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatmentMichael E Henry, Marc J Kaufman, John Hennen, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 23, 2005
Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptomsChristopher J Kratochvil, Jeffrey H Newcorn, L Eugene Arnold, et al.
Clinical and Translational Science|November 24, 2019
Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine TreatmentChi-Chung Li, Tiffini Voss, Ken Kowalski, et al.
The Journal of Pediatrics|April 7, 2005
Patterns of brain injury in term neonatal encephalopathySteven P Miller, Vijay Ramaswamy, David Michelson, et al.
Alzheimer'S Research & Therapy|August 8, 2019
Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's diseaseMichael F Egan, Yuki Mukai, Tiffini Voss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 25, 2009
Under the radar: balamuthia amebic encephalitisFrederick L Schuster, Shigeo Yagi, Shilpa Gavali, et al.
Cephalalgia : an International Journal of Headache|June 20, 2012
Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment designTony W Ho, Eric Pearlman, Donald Lewis, et al.
The Lancet. Neurology|April 1, 2014
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trialDavid Michelson, Ellen Snyder, Erin Paradis, et al.
Psychopharmacology|March 8, 2017
Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 dataW Joseph Herring, Kathryn M Connor, Ellen Snyder, et al.
Cephalalgia : an International Journal of Headache|May 1, 2015
Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraineTony W Ho, Andrew P Ho, Yang Joy Ge, et al.
Pageof 9